Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors
Vicki Fung(Massachusetts General Hospital), Andrew A. Nierenberg(Andrews University), Richard C. Shelton(University of Maryland, College Park), Joseph R. Calabrese(Case Western Reserve University), Masoud Kamali(Massachusetts General Hospital), Lindsay Overhage(Cambridge Health Alliance), Thilo Deckersbach(Harvard University), Terence A. Ketter(Stanford University), Noreen A. Reilly-Harrington(Massachusetts General Hospital), William V. Bobo(Mayo Clinic in Florida), Keming Gao(University Hospitals of Cleveland), Louisa G. Sylvia(Massachusetts General Hospital), Michael E. Thase(Unknown), Mauricio Tohen(University of New Mexico)
Cited by 44
Related Papers
Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder
|Bipolar Disorders|2018|1.8k
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder
|Nature Genetics|2008|1.3k
Mood Disorders in the Medically Ill: Scientific Review and Recommendations
|Biological Psychiatry|2005|1.1k
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
|New England Journal of Medicine|2007|925
The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders
|American Journal of Psychiatry|2013|754